HIGHLIGHTS
In patients with HCM and symptomatic LVOT-obstruction, first treatment with disopyramide leads to a marked reduction of LVOT gradients, with a slight decrease of resting ejection fraction and a modest increase of corrected QT interval, highlighting high efficacy and safety.
In single cardiomyocytes and intact trabeculae from surgical samples of patients with obstructive HCM, in vitro treatment with 5 mmol/l disopyramide lowered force and Ca2 D transients while reducing action potential duration and the rate of arrhythmic afterdepolarizations.
These effects are mediated by the combined inhibition of peak and late Na D currents, L-type Ca 2D current, delayed-rectifier K D current, and ryanodine receptors.
In addition to the negative inotropic effect of disopyramide, in vitro results suggest additional antiarrhythmic actions.
SUMMARY
Disopyramide is effective and safe in patients with obstructive hypertrophic cardiomyopathy. However, its cellular and molecular mechanisms of action are unknown. We tested disopyramide in cardiomyocytes from the septum of surgical myectomy patients: disopyramide inhibits multiple ion channels, leading to lower Ca transients and force, and shortens action potentials, thus reducing cellular arrhythmias. The electrophysiological profile of disopyramide explains the efficient reduction of outflow gradients but also the limited prolongation of the QT interval and the absence of arrhythmic side effects observed in 39 disopyramide-treated patients. In conclusion, our results support the idea that disopyramide is safe for outpatient use in obstructive patients. since the first reports in the early 1980s and after confirmatory studies of its efficacy and safety (2) (3) (4) (5) (6) .
In patients with obstructive HCM and limiting symptoms, disopyramide in addition to a beta blocker has a Class I recommendation by the 2014 European Society of Cardiology guidelines and a Class IIa recommendation by the 2011 American Heart Association/American College of Cardiology Foundation guidelines (7, 8) . Most recently, safe initiation in outpatients has been retrospectively demonstrated (9) .
Its practical use and current place in the armamentarium for obstructive HCM has been described and reviewed elsewhere (10, 11) .
Despite its active use since the 1980s, there has been little work on the intracellular mechanism of therapeutic effects of disopyramide beyond its categorization as a type Ia antiarrhythmic, that is, as Na channel blocker with action potential (AP)-prolonging effects (12, 13) . A paper in the late 1980s suggested an effect on sarcolemmal Ca influx and efflux mediated by the Na þ /Ca 2þ exchanger (NCX) (14) . In light of its potent negative inotropic effects, it is not known whether the drug has additional direct effects on Ca 2þ current, Ca 2þ release from the sarcoplasmic reticulum (SR) or on the actin-myosin interaction and the effects of disopyramide in human HCM cardiomyocytes have not been characterized.
We previously analyzed the electromechanical profile of cardiomyocytes isolated from myectomy samples of patients with obstructive HCM (15, 16) .
When compared with control cells, HCM cardiomyocytes showed prolonged AP, frequent afterdepolarizations, slower Ca 2þ transients, and elevated diastolic Ca 2þ concentration, largely determined by overexpression of the late Na þ current (I NaL ). Indeed, these electromechanical abnormalities were reversed by the I NaL inhibitor ranolazine, with beneficial effects on diastolic function and cellular arrhythmias (15, 16) .
In the present study, we sought to uncover mechanistic insights by applying electrophysiological and biophysical techniques to evaluate the effects of disopyramide on ion fluxes, afterdepolarizations, and twitch tension in isolated HCM cardiomyocytes and intact trabeculae harvested from patients undergoing surgical septal myectomy. In a translational approach, the in vitro study was combined with the first prospective characterization of the electrocardiographic and echocardiographic changes in patients with obstructive HCM started on disopyramide treatment.
METHODS

Detailed methods are available in the Supplemental
Appendix data supplement. 
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Disopyramide in HCM: Cellular Mechanisms protocols. In brief, we evaluated the inotropic responses to increased pacing frequencies and the kinetics of isometric twitches. Resting sarcomere length was 1.9 AE 0.1 mm.
DEMEMBRANATED TRABECULAE. Ventricular trabeculae were skinned by exposure to 0.5% Triton X100
solution. Demembranated trabeculae were employed to obtain calcium concentration (pCa)-tension curves as previously described (15, 18, 19 Ventricular myocytes were isolated from the hearts of 4 transgenic HCM mice carrying the R92Q troponin-T mutation, as previously described (18, 19) . for automated analysis (21) .
STATISTICS (STUDIES ON CELLS AND TRABECULAE).
None of the 20 consecutively collected patient samples was excluded from the final analysis. However, we were unable to perform all the different experi- of patients' samples from which they were isolated.
Results from each dataset are expressed as mean AE SEM. Statistical analysis, taking into account non-Gaussian distribution, inequality of variances and within-subject correlation, was performed as previously described (15, 18 Thirty-nine patients were begun on disopyramide (age 66 AE 10 years; 59% were female). The mean daily dosage of disopyramide after 3 months was 497 AE 87 mg/day. No patient had clinically significant arrhythmia or organ toxicity during the study period.
In 9 patients (23%), disopyramide was ineffective or there were limiting vagolytic side effects that led to termination of drug before 3 months. ECG parameters before and at a median of 96 days after disopyramide initiation are shown in Table 1 . There were prolongations in the QTc, QRS, JT, and PR intervals, but no significant change in heart rate at 3 months. The mean QTc interval increased from 458 AE 22 ms to 486 AE 27 ms (p < 0.001). Mean QTc prolongation was 27 ms, which corresponds to a 5.8% increase from baseline. Patients with an initially longer QTc
Disopyramide in HCM: Cellular Mechanisms HR ¼ heart rate; JT ¼ time from the end of the QRS complex to the end of the T wave; PR ¼ time from the beginning the P wave to the beginning of the QRS complex. Values are mean AE SD. The p values were calculated using paired Student's t-test. Comparison between echocardiographic parameters obtained before disopyramide initiation (pre-disopyramide) and at the end of study (post-disopyramide).
LVEDV ¼ left ventricular end-diastolic volume; LVEF¼ ejection fraction; LVESV ¼ end-systolic volume; Lateral TDI e 0 (e 0 L) ¼ early diastolic downward velocity of the lateral (free wall) mitral annulus measured at tissue Doppler; Septal TDI e 0 (e 0 S) ¼ early diastolic downward velocity of the medial (septal) mitral annulus measured at tissue Doppler; Transmitral A ¼ late diastolic transmitral flow velocity (during atrial systole); Transmitral E ¼ early diastolic flow velocity through the mitral valve. Coppini et al.
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As expected, the drug displayed a consistent negative inotropic effect ( Figure 1A) . To assess the concentration dependency of this effect, we exposed the muscles to different concentrations of disopyramide ( Figure 1B) . Calculated disopyramide concentration at 50% of maximal effect on isometric twitch amplitude was 5.29 AE 1.55 mmol/l. We therefore decided to employ the drug at 5 mmol/l for all the following experiments; notably, 5 mmol/l corresponds to the average plasma concentration of disopyramide measured in patients under a standard treatment regimen (25) . Importantly, 5 mmol/l disopyramide hastened isometric twitch kinetics in HCM trabeculae: both time to peak and relaxation time were reversibly shortened by the application of the drug ( Figures 1A and 1C). We tested the effects of disopyramide at different stimulation frequencies ( Figure 1D ): the reduction of steady-state isometric twitch force was more pronounced at higher pacing rates as compared with lower rates. Isometric twitch force was reduced by 33 AE 5% at 0.5 Hz (30 beats/min) and by 62 AE 10% at 
N O V E M B E R 2 0 1 9 : 7 9 5 -8 1 3 Table 3 ) at all frequencies ( Figure 3B ) and the effect was more pronounced at lower rates. For instance, average AP shortening at 0.1 Hz was 27 AE 5% and is comparable to that observed in human HCM cardiomyocytes with 10 mmol/l of ranolazine (17) . In addition, disopyramide reduced AP amplitude and upstroke speed ( Figure 4A ), whereas I NaL was estimated by integrating the residual inward current (50 to 800 ms after onset) ( Figure 4B) . In HCM myocytes, disopyramide (5 mmol/l) reduced peak Na þ current by 22 AE 4% and greatly decreased I NaL integral by 45 AE 6% (21 myocytes, n ¼ 5).
We then assessed the effects of disopyramide on I K , measured at steady state during depolarization at different potentials ( Figure 4C ). Disopyramide Coppini et al. 
blue). (B,D)
Mean AE SE from 28 hypertrophic cardiomyopathy cardiomyocytes from 8 patients with hypertrophic cardiomyopathy (ID# 3 to 6, 9, and 11 to 13). **0.01 > p > 0.001; ***p < 0.001; linear-mixed models.
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Disopyramide in HCM: Cellular Mechanisms (A, left) Representative peak Na current traces elicited at À10 mV from À120 mV resting potential, in a hypertrophic cardiomyopathy cardiomyocyte in the absence (black) and presence of disopyramide (Diso) (blue trace). (Right) Average peak Na þ current (I Na-peak ) density at À10 mV; effect of disopyramide. (B, left) Representative late Na þ current (I NaL ) traces elicited at -10 mV from À120 mV resting potential, in the absence and presence of disopyramide. Coppini et al.
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Disopyramide in HCM: Cellular Mechanisms LV emptying due to loss of obstruction. Thus, the impact of negative inotropic drugs on end-systolic volume will be very limited, explaining the modest reduction of ejection fraction.
In the current study, disopyramide lowered resting LVOT gradients from mean 58 to 25 mm Hg after 3 months. This was similar to a prior report in 221 patients using disopyramide with an average dose of 
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